Faculty Collaboration Database

Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2010 Mar;16(3):395-402

Date

11/20/2009

Pubmed ID

19922808

Pubmed Central ID

PMC2833344

DOI

10.1016/j.bbmt.2009.11.007

Scopus ID

2-s2.0-75749106529 (requires institutional sign-in at Scopus site)   50 Citations

Abstract

Blacks are twice as likely to develop and die from multiple myeloma (MM), and are less likely to receive an autologous hematopoietic-cell transplant (AHCT) for MM compared to Whites. The influence of race on outcomes of AHCT for MM is not well described. We compared the probability of overall survival (OS), progression-free survival (PFS), disease progression, and nonrelapse mortality (NRM) among Black (N=303) and White (N=1892) recipients of AHCT for MM, who were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 1995 to 2005. The Black cohort was more likely to be female, and had better Karnofsky performance scores, but lower hemoglobin and albumin levels at diagnosis. Black recipients were younger and more likely to be transplanted later in their disease course. Disease stage and treatment characteristics prior to AHCT were similar between the 2 groups. Black and White recipients had similar probabilities of 5-year OS (52% versus 47%, P=.19) and PFS (19% versus 21%, P=.64) as well as cumulative incidences of disease progression (72% versus 72%, P=.97) and NRM (9% versus 8%, P=.52). In multivariate analyses, race was not associated with any of these endpoints. Black recipients of AHCT for MM have similar outcomes compared to Whites, suggesting that the reasons underlying lower rates of AHCT in Blacks need to be studied further to ensure equal access to effective therapy.

Author List

Hari PN, Majhail NS, Zhang MJ, Hassebroek A, Siddiqui F, Ballen K, Bashey A, Bird J, Freytes CO, Gibson J, Hale G, Holmberg L, Kamble R, Kyle RA, Lazarus HM, LeMaistre CF, Loberiza F, Maiolino A, McCarthy PL, Milone G, Omondi N, Reece DE, Seftel M, Trigg M, Vesole D, Weiss B, Wiernik P, Lee SJ, Rizzo JD, Mehta P

Authors

Parameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of Wisconsin
J. Douglas Rizzo MD, MS Director, Center Associate Director, Professor in the Medicine department at Medical College of Wisconsin
Mei-Jie Zhang PhD Professor in the Institute for Health and Equity department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Age Factors
Aged
Aged, 80 and over
Disease Progression
Disease-Free Survival
Drug Therapy
Female
Hematopoietic Stem Cell Transplantation
Humans
Kaplan-Meier Estimate
Karnofsky Performance Status
Male
Middle Aged
Multiple Myeloma
Recurrence
Transplantation, Autologous
Treatment Outcome